Top 10 Undervalued Stocks To Watch For 2019

The reason why the growth stocks do so much better is that they seem to show gains in value in the hundreds of percent each decade. In contrast, it is an unusual bargain that is as much as 50 percent undervalued. The cumulative effect of this simple arithmetic should be obvious. – Philip Fisher (the Father of Growth Investing)

On Jan 05, 2018, the share price of Crispr Therapeutics (NASDAQ:CRSP), a bioscience focusing on gene-editing and CAR-T to treat serious conditions such as cancers and genetic diseases, continued its rally. The stock added another $2.90 (over 12% profits) to value at $26.81 for the said trading session. Since we recommended the company on Nov. 27, 2017 (just over a month) to subscribers of Integrated BioSci Investing, the stock added another $7.26 (or 37% in capital appreciation). This robust run-up is interesting because, on Jan. 04, 2018, the company announced that the 5M additional common shares issued on Jan 03 will be priced at $22.75.

Top 10 Undervalued Stocks To Watch For 2019: Internap Network Services Corporation(INAP)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Internap (NASDAQ:INAP) issued its quarterly earnings data on Thursday. The information technology services provider reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.13), MarketWatch Earnings reports. The business had revenue of $74.20 million for the quarter, compared to analyst estimates of $73.99 million. Internap had a negative return on equity of 271.76% and a negative net margin of 16.15%. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.02) earnings per share.

  • [By Shane Hupp]

    GDS (NASDAQ: INAP) and Internap (NASDAQ:INAP) are both business services companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Internap (INAP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Shares of Internap Corp (NASDAQ:INAP) saw unusually-strong trading volume on Tuesday . Approximately 1,086,029 shares traded hands during mid-day trading, an increase of 306% from the previous session’s volume of 267,673 shares.The stock last traded at $5.85 and had previously closed at $5.32.

  • [By Stephan Byrd]

    Internap Corp (NASDAQ:INAP) has received an average rating of “Buy” from the six analysts that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $28.00.

Top 10 Undervalued Stocks To Watch For 2019: KLX Inc.(KLXI)

Advisors’ Opinion:

  • [By Logan Wallace]

    OppenheimerFunds Inc. decreased its position in KLX Inc (NASDAQ:KLXI) by 16.2% in the 1st quarter, Holdings Channel reports. The firm owned 7,067 shares of the aerospace company’s stock after selling 1,367 shares during the period. OppenheimerFunds Inc.’s holdings in KLX were worth $502,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Rich Smith]

    KLX Inc. (NASDAQ:KLXI) stock closed 15.2% lower on Monday. That sounds like bad news, but really isn’t. Here’s why.

    So what

    KLX is a strange beast, as it comprises two main business units. The Aerospace Solutions Group distributes small airplane components such as bolts, clips, hinges, and screws. With $1.4 billion in annual sales, this is KLX’s largest business unit — and it’s selling out to Boeing in a $4.25 billion deal initially expected to close sometime in this current third quarter of 2018  — later postponed to Q4.

  • [By Shane Hupp]

    KLX (NASDAQ:KLXI) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Friday.

  • [By Max Byerly]

    BidaskClub downgraded shares of KLX (NASDAQ:KLXI) from a buy rating to a hold rating in a report released on Tuesday morning.

    KLXI has been the subject of several other reports. SunTrust Banks cut shares of KLX from a buy rating to a hold rating and set a $53.00 target price for the company. in a report on Wednesday, May 2nd. Zacks Investment Research cut shares of KLX from a buy rating to a hold rating in a report on Saturday, February 17th. TheStreet cut shares of KLX from a b rating to a c+ rating in a report on Tuesday, March 6th. Finally, Jefferies Group upgraded shares of KLX from a hold rating to a buy rating in a report on Wednesday, March 7th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $66.50.

Top 10 Undervalued Stocks To Watch For 2019: Discover Financial Services(DFS)

Advisors’ Opinion:

  • [By Matthew Cochrane]

    Over the past several quarters, Discover Financial Services (NYSE:DFS) has struggled to strike the proper balance between growing its loan portfolios and keeping its credit default risks in check. At least, that’s what Wall Street would have you believe. Discover’s management, however, maintains credit risk concerns are overblown. Meanwhile, the company continues to grow its loan portfolios at steady clips.

  • [By Joseph Griffin]

    DFS Furniture (LON:DFS)‘s stock had its “buy” rating reissued by analysts at Peel Hunt in a research note issued to investors on Thursday.

  • [By ]

    Selected examples: (BXP) , (DFS) , (HST) , (MA) , (TXN) , (USB) .

    Inflation Is a Key Risk

    Execs were most worried about inflation, as they should be.

Top 10 Undervalued Stocks To Watch For 2019: Gulfport Energy Corporation(GPOR)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Liberty Mutual Group Asset Management Inc. lowered its stake in Gulfport Energy Co. (NASDAQ:GPOR) by 22.3% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,452 shares of the oil and gas producer’s stock after selling 9,320 shares during the quarter. Liberty Mutual Group Asset Management Inc.’s holdings in Gulfport Energy were worth $313,000 at the end of the most recent reporting period.

  • [By Joseph Griffin]

    Gulfport Energy (NASDAQ: GPOR) and Callitas Health (OTCMKTS:MPHMF) are both small-cap oils/energy companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

  • [By Shane Hupp]

    Gulfport Energy Co. (NASDAQ:GPOR) saw some unusual options trading activity on Monday. Stock investors bought 43,045 call options on the stock. This is an increase of approximately 1,866% compared to the typical volume of 2,190 call options.

  • [By Max Byerly]

    Liberum Capital reissued their hold rating on shares of Great Portland Estates (LON:GPOR) in a research note published on Wednesday morning.

    GPOR has been the subject of a number of other reports. Barclays increased their price objective on shares of Great Portland Estates from GBX 560 ($7.51) to GBX 580 ($7.78) and gave the company an underweight rating in a report on Thursday, February 22nd. Deutsche Bank reaffirmed a hold rating on shares of Great Portland Estates in a report on Friday, March 2nd. Goldman Sachs Group cut their price objective on shares of Great Portland Estates from GBX 675 ($9.06) to GBX 665 ($8.92) and set a neutral rating for the company in a report on Wednesday, March 14th. Morgan Stanley increased their price objective on shares of Great Portland Estates from GBX 620 ($8.32) to GBX 660 ($8.86) and gave the company an underweight rating in a report on Tuesday, March 13th. Finally, Citigroup raised their target price on shares of Great Portland Estates from GBX 700 ($9.39) to GBX 735 ($9.86) and gave the company a neutral rating in a report on Wednesday, May 2nd. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. Great Portland Estates has a consensus rating of Hold and a consensus target price of GBX 662.15 ($8.88).

  • [By Logan Wallace]

    Gulfport Energy Co. (NASDAQ:GPOR) – Stock analysts at Seaport Global Securities upped their Q3 2018 earnings per share estimates for Gulfport Energy in a research note issued on Wednesday, May 23rd. Seaport Global Securities analyst M. Kelly now expects that the oil and gas producer will post earnings of $0.33 per share for the quarter, up from their prior estimate of $0.22. Seaport Global Securities also issued estimates for Gulfport Energy’s Q4 2018 earnings at $0.43 EPS, FY2018 earnings at $1.63 EPS, Q2 2019 earnings at $0.28 EPS, Q3 2019 earnings at $0.28 EPS, Q4 2019 earnings at $0.35 EPS and FY2019 earnings at $1.22 EPS.

  • [By Paul Ausick]

    Gulfport Energy Corp. (NASDAQ: GPOR) traded down about 10% Tuesday and posted a new 52-week low of $10.90 after closing Monday at $12.12. The stock’s 52-week high is $9.75. Volume was over 12 million, nearly four times the daily average of about 3.4million shares. The company had no specific news announced its capital budget and a stock repurchase program after markets closed Monday.

Top 10 Undervalued Stocks To Watch For 2019: ITUS Corporation(ITUS)

Advisors’ Opinion:

  • [By Joseph Griffin]

    ITUS Corp (NASDAQ:ITUS) CEO Amit Kumar bought 4,480 shares of ITUS stock in a transaction dated Wednesday, September 12th. The shares were purchased at an average cost of $3.99 per share, for a total transaction of $17,875.20. Following the completion of the transaction, the chief executive officer now owns 128,888 shares of the company’s stock, valued at approximately $514,263.12. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

Top 10 Undervalued Stocks To Watch For 2019: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Shane Hupp]

    These are some of the media headlines that may have effected Accern’s scoring:

    Get Ultragenyx Pharmaceutical alerts:

    Burosumab Improves Outcomes in Children with XLH in Phase 2 Trial (raredr.com) RARE Stock Is on the Verge of Breaking Out Toward Higher Prices (profitconfidential.com) Burosumab may benefit children with X-linked hypophosphatemia (medicalxpress.com) A Look Inside the Quant Data For Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) (parkcitycaller.com) Ultragenyx Pharmaceutical Inc. (RARE)- Stock in the Trader’s Radar (nasdaqfortune.com)

    A number of research firms have recently weighed in on RARE. ValuEngine raised Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday. BidaskClub raised Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 19th. Barclays raised Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $62.00 to $74.00 in a report on Friday, May 11th. Goldman Sachs Group began coverage on Ultragenyx Pharmaceutical in a report on Thursday, May 10th. They set a “neutral” rating and a $63.00 target price for the company. Finally, Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $70.06.

  • [By Shane Hupp]

    Ultragenyx Pharmaceutical (NASDAQ:RARE) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Ultragenyx launched its second drug, Crysvita, in the United States to treat X-linked hypophosphatemia (XLH) in April. We are optimistic on the drug’s uptake. The drug was also approved in the EU in February on a conditional basis. In May, the company announced positive phase II data from the drug in pediatric setting, but according to the FDA those were not sufficient to support an NDA. Thus, the company is in discussions with FDA and EMA, which would provide further clarity regarding whether an additional study would be required for the approval. The company also remains focused on its two-gene therapy programs — DTX301 for ornithine transcarbamylase deficiency and DTX401 for glycogen storage disease type Ia. However, developmental or regulatory setbacks could result in higher operating expenses and the need for additional capital. Loss estimates have narrowed ahead of  Q3 earnings release.”

  • [By Joseph Griffin]

    BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a report released on Monday.

    A number of other brokerages have also recently weighed in on RARE. JPMorgan Chase restated an overweight rating and issued a $66.00 price objective (down from $68.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an in-line rating to an outperform rating in a research note on Monday, January 22nd. Stifel Nicolaus restated a buy rating and issued a $74.00 price objective (down from $85.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Wednesday, April 4th. Finally, Wedbush reiterated a positive rating and set a $71.00 target price (up from $64.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, April 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of Buy and an average price target of $69.76.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Chris Lange]

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is expected to report Phase 2 data from all its tumor-induced osteomalacia patients. Shares of Ultragenyx closed Friday at $76.87, in a 52-week range of $41.67 to $86.10 and with a consensus analyst target of $68.74.

Top 10 Undervalued Stocks To Watch For 2019: Cytosorbents Corporation(CTSO)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Cytosorbents Corp (NASDAQ:CTSO) COO Vincent Capponi sold 9,565 shares of the company’s stock in a transaction that occurred on Tuesday, August 28th. The shares were sold at an average price of $13.00, for a total value of $124,345.00. Following the completion of the transaction, the chief operating officer now owns 342,333 shares in the company, valued at approximately $4,450,329. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

  • [By Motley Fool Transcribers]

    Cytosorbents Corp  (NASDAQ:CTSO)Q4 2018 Earnings Conference CallMarch 07, 2019, 4:45 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Shane Hupp]

    Cytosorbents (NASDAQ:CTSO) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Thursday.

Top 10 Undervalued Stocks To Watch For 2019: Ebix, Inc.(EBIX)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Wall Street seemed to phone it in on Monday, with low volume and fairly modest moves for most major benchmarks reflecting the fact that many federal and state government offices were closed for a holiday. Interest rates stabilized after a substantial jump last week, but market participants are still working through the potential consequences of the rate rise that resulted in 10-year Treasury yields hitting their highest levels since the early 2010s. Moreover, some negative news regarding individual companies weighed on sentiment. Square (NYSE:SQ), Ebix (NASDAQ:EBIX), and iRobot (NASDAQ:IRBT) were among the worst performers on the day. Here’s why they did so poorly.

  • [By Motley Fool Transcribers]

    Ebix Inc  (NASDAQ:EBIX)Q4 2018 Earnings Conference CallMarch 01, 2019, 11:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Max Byerly]

    Shares of Ebix Inc (NASDAQ:EBIX) were down 5.8% during mid-day trading on Tuesday . The stock traded as low as $57.66 and last traded at $61.47. Approximately 18,499 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 189,931 shares. The stock had previously closed at $58.10.

  • [By Shane Hupp]

    Ebix (NASDAQ: EBIX) and Godaddy (NYSE:GDDY) are both computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

  • [By Shane Hupp]

    Shares of Ebix Inc (NASDAQ:EBIX) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $100.00.

  • [By Ethan Ryder]

    Ebix (NASDAQ:EBIX) issued its earnings results on Wednesday. The technology company reported $0.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.01), MarketWatch Earnings reports. The business had revenue of $108.23 million for the quarter, compared to analysts’ expectations of $106.81 million. Ebix had a return on equity of 20.67% and a net margin of 27.65%. Ebix’s revenue for the quarter was up 36.8% on a year-over-year basis.

Top 10 Undervalued Stocks To Watch For 2019: Hanesbrands Inc.(HBI)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Wall Street started the week on a muted note on Monday, as major benchmarks generally closed slightly down. Much of the attention among investors was on the bond market, where 10-year Treasury yields rose as high as 2.99%, signaling to some the possibility of much higher financing costs that could punish companies that overextended their balance sheets with debt when rates were much lower. Yet some individual companies had good news that sent their shares higher. McDermott International (NYSE:MDR), Box (NYSE:BOX), and Hanesbrands (NYSE:HBI) were among the best performers on the day. Here’s why they did so well.

  • [By Stephan Byrd]

    Morgan Stanley increased its position in shares of Hanesbrands Inc. (NYSE:HBI) by 13.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,095,675 shares of the textile maker’s stock after acquiring an additional 362,960 shares during the period. Morgan Stanley owned about 0.86% of Hanesbrands worth $68,166,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Hanesbrands (HBI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Hanesbrands (HBI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Keith Noonan]

    The strategy might not produce huge gains overnight, but patient investors can see strong returns with a value-focused, buy-to-hold approach to dividend stocks. Within that mold, investors seeking solid, income-generating stocks should consider establishing or adding to positions in Hanesbrands (NYSE:HBI) and AT&T (NYSE:T) — two companies that are consistently profitable, trade at non-prohibitive valuations, and pay sizable dividends. 

  • [By Keith Noonan]

    For this dive into promising income-generating stocks, I’ll be looking at three companies that have recently been making headlines for their strong performances. Two are technology giants that are benefiting from the growth of recurring revenue streams — Cisco Systems (NASDAQ:CSCO) and Microsoft (NASDAQ:MSFT) — and the other is an apparel stalwart on the rebound as one of its key lines is heating up — Hanesbrands (NYSE:HBI).

Top 10 Undervalued Stocks To Watch For 2019: The First of Long Island Corporation(FLIC)

Advisors’ Opinion:

  • [By Ethan Ryder]

    1ST RES BK EXTO/SH (OTCMKTS:FRSB) and First of Long Island (NASDAQ:FLIC) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.

  • [By Stephan Byrd]

    COPYRIGHT VIOLATION WARNING: “First of Long Island Corp (FLIC) Position Trimmed by ClariVest Asset Management LLC” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at www.tickerreport.com/banking-finance/4167612/first-of-long-island-corp-flic-position-trimmed-by-clarivest-asset-management-llc.html.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on First of Long Island (FLIC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    First of Long Island Corp (NASDAQ:FLIC) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $21.30 and last traded at $21.60, with a volume of 237 shares. The stock had previously closed at $21.50.

  • [By Stephan Byrd]

    First of Long Island (NASDAQ:FLIC) and 1ST RES BK EXTO/SH (OTCMKTS:FRSB) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Leave a Reply

Your email address will not be published. Required fields are marked *